KYNB NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Kyntra Bio, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 7.27 USD
8.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -0.4% below the Trend Line and sits at 15.1% of its 52-week range. The latest completed week returned 8.0%, after a -4.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal.

Setup score 25 out of 100
Latest Close 7.27 USD 7 Aug 2026
1W Return 8.0% latest completed week
4W Return -4.4% short-term follow-through
12W Return 6.6% quarterly tape
Trend Breadth 21.2% 11 of 52 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 8.0% Latest completed week; four-week move -4.4%. Indicator stack 12/55 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 53/100 51 relevant articles in the latest sentiment read. Event risk 13 Aug Latest stored earnings date was 13 Aug 2026.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -0.4% below the Trend Line and sits at 15.1% of its 52-week range. The latest completed week returned 8.0%, after a -4.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0812-week average 0.05

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.08Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -4.4% over four weeks, 6.6% over 12 weeks, and -16.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W8.0%
4W-4.4%
12W6.6%
26W-11.6%
52W-16.5%
Active trend streak0 weeks
Active weeks in one year11
Trend breadth21.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.48Latest activity-pressure read.
Pressure change-48.4%Four-week change in activity pressure.
Leadership-26.28Latest relative-leadership reading.
RS change-6.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 74%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value52/100Relative valuation strength. Underlying universe rank 49; rank 1 is best.
Quality49/100Profitability and accounting quality. Underlying universe rank 52; rank 1 is best.
Momentum52/100Medium-term price momentum. Underlying universe rank 49; rank 1 is best.
Growth52/100Revenue and earnings growth. Underlying universe rank 49; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
0.2x
Price divided by trailing earnings.
Price / sales
4.0x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-46.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
45.1%
Gross profit retained from each unit of revenue.
Operating margin
-759.4%
Operating profit retained from revenue.
Free-cash-flow margin
-287.1%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
13.4%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
13.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 51 relevant articles.

11 positive · 35 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13 AugLatest stored earnings date was 13 Aug 2026.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-42.3%Distance below the 52-week high.
13-week volatility4.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+11.7%Week of 20 Feb.
Worst week-16.7%Week of 27 Feb.
Latest week+8.0%Week of 7 Aug.

Shape of recent returns

Strong gains6
Modest gains5
Flat weeks0
Modest losses9
Sharp losses6
Recent vol4.8%13-week weekly-return volatility.
Base vol6.6%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew5.3% / -4.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape22/100

Trend, activity pressure, participation, and risk combine to a 22/100 tape read.

 Indicator analysis25/100

Latest 12-week confirmation: trend 0/12, activity pressure 9/12, relative leadership 0/12.

Activity pressure 0.08; No reversal markers Factors51/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 49 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment53/100

Weighted news tone is neutral across 51 relevant articles.

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy? Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13 Aug

Latest stored earnings date was 13 Aug 2026.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20267.27 USD8.0%7.30 USD15.24 USD0.48-26.2827.8KOff
31 Jul 20266.73 USD-4.3%7.36 USD15.41 USD0.62-28.8030.7KOff
24 Jul 20267.03 USD-2.8%7.44 USD15.68 USD0.91-25.5020.3KOff
17 Jul 20267.23 USD-4.9%7.50 USD15.94 USD1.05-24.9151.8KOff
10 Jul 20267.61 USD-0.3%7.55 USD16.23 USD0.92-24.64121.9KOff
3 Jul 20267.63 USD5.4%7.58 USD16.59 USD0.84-23.2837.0KOff
26 Jun 20267.24 USD8.1%7.60 USD16.98 USD0.61-26.52116.4KOff
19 Jun 20266.70 USD-6.0%7.65 USD17.36 USD0.25-35.0040.4KOff
12 Jun 20267.13 USD6.3%7.71 USD19.89 USD0.27-29.16510.8KOff
5 Jun 20266.71 USD-2.8%7.76 USD22.53 USD-0.07-32.0537.9KOff
29 May 20266.90 USD-1.3%7.91 USD25.20 USD-0.17-33.7629.2KOff
22 May 20266.99 USD2.5%8.05 USD28.02 USD-0.14-31.3842.2KOff
15 May 20266.82 USD-1.9%8.18 USD30.66 USD-0.37-32.8257.2KOff
8 May 20266.95 USD-2.0%8.29 USD33.43 USD-0.50-32.2336.0KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context